Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis.

Artificial intelligence Cardiotoxicity Forecasting Lung neoplasms Machine learning Outcome

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 23 09 2021
accepted: 17 02 2022
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 5 3 2022
Statut: epublish

Résumé

To maximize the likelihood of positive outcome in non-small-cell lung cancer (NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the possibilities of damage to normal tissues, such as the heart. High-quality data-driven evidence regarding appropriate risk stratification strategies is still scarce. The aim of this review is to summarize and appraise available prediction models for treatment-induced cardiac events in patients with NSCLC. A systematic search of MEDLINE was performed using a Boolean combination of appropriate truncation and indexing terms related to "NSCLC", "prediction models", "cardiac toxicity", and "treatment modalities". The following exclusion criteria were applied: sample-size of less than 100, no significant predictors in multivariate analysis, lack of model specifications, and case-mix studies. The generic inverse variance method was used to pool the summary effect estimate for each predictor. The quality of the papers was assessed using the Prediction model Risk Of Bias Assessment Tool. Of the 3,056 papers retrieved, 28 prediction models were identified, including seven for (chemo-)radiotherapy, one for immunotherapy, and 20 for surgical resection. Forty-one distinct predictors were entered in the prediction models. The pooled effect estimate of the mean heart dose (HR = 1.06, 95%CI:1.04-1.08) and history of cardiovascular diseases (HR = 3.1, 95%CI:1.8-5.36) were shown to significantly increase the risk of developing late cardiac toxicity after (chemo-)radiotherapy. Summary estimates of age (OR = 1.17, 95%CI:1.06-1.29), male gender (OR = 1.61, 95%CI:1.4-1.85), and advanced stage (OR = 1.34, 95%CI:1.06-1.69) were significantly associated with higher risk of acute cardiac events after surgery. Risk of bias varied across studies, but analysis was the most concerning domain where none of the studies were judged to be low risk. This review highlights the need for a robust prediction model which can inform patients and clinicians about expected treatment-induced heart damage. Identified clues suggest incorporation of detailed cardiac metrics (substructures' volumes and doses).

Sections du résumé

BACKGROUND BACKGROUND
To maximize the likelihood of positive outcome in non-small-cell lung cancer (NSCLC) survivors, potential benefits of treatment modalities have to be weighed against the possibilities of damage to normal tissues, such as the heart. High-quality data-driven evidence regarding appropriate risk stratification strategies is still scarce. The aim of this review is to summarize and appraise available prediction models for treatment-induced cardiac events in patients with NSCLC.
METHODS METHODS
A systematic search of MEDLINE was performed using a Boolean combination of appropriate truncation and indexing terms related to "NSCLC", "prediction models", "cardiac toxicity", and "treatment modalities". The following exclusion criteria were applied: sample-size of less than 100, no significant predictors in multivariate analysis, lack of model specifications, and case-mix studies. The generic inverse variance method was used to pool the summary effect estimate for each predictor. The quality of the papers was assessed using the Prediction model Risk Of Bias Assessment Tool.
RESULTS RESULTS
Of the 3,056 papers retrieved, 28 prediction models were identified, including seven for (chemo-)radiotherapy, one for immunotherapy, and 20 for surgical resection. Forty-one distinct predictors were entered in the prediction models. The pooled effect estimate of the mean heart dose (HR = 1.06, 95%CI:1.04-1.08) and history of cardiovascular diseases (HR = 3.1, 95%CI:1.8-5.36) were shown to significantly increase the risk of developing late cardiac toxicity after (chemo-)radiotherapy. Summary estimates of age (OR = 1.17, 95%CI:1.06-1.29), male gender (OR = 1.61, 95%CI:1.4-1.85), and advanced stage (OR = 1.34, 95%CI:1.06-1.69) were significantly associated with higher risk of acute cardiac events after surgery. Risk of bias varied across studies, but analysis was the most concerning domain where none of the studies were judged to be low risk.
CONCLUSION CONCLUSIONS
This review highlights the need for a robust prediction model which can inform patients and clinicians about expected treatment-induced heart damage. Identified clues suggest incorporation of detailed cardiac metrics (substructures' volumes and doses).

Identifiants

pubmed: 35243024
doi: 10.1016/j.ctro.2022.02.007
pii: S2405-6308(22)00010-6
pmc: PMC8881199
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

134-144

Informations de copyright

© 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Ann Thorac Surg. 2010 Aug;90(2):368-74
pubmed: 20667313
J Cardiothorac Surg. 2012 Jan 10;7:4
pubmed: 22233837
Front Oncol. 2018 Oct 10;8:433
pubmed: 30364202
Interact Cardiovasc Thorac Surg. 2017 Feb 1;24(2):260-264
pubmed: 27803121
BMC Med Res Methodol. 2019 Mar 19;19(1):64
pubmed: 30890124
Chest. 2002 Jun;121(6):1890-7
pubmed: 12065354
J Thorac Cardiovasc Surg. 2010 Oct;140(4):764-8
pubmed: 20691999
J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987
pubmed: 31196455
J Thorac Dis. 2017 Oct;9(10):3456-3457
pubmed: 29268314
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
Ann Thorac Surg. 2019 Feb;107(2):603-609
pubmed: 30278164
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Lung Cancer. 2020 Dec;150:172-177
pubmed: 33186859
Eur J Cardiothorac Surg. 2014 Feb;45(2):247-50
pubmed: 23921159
Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):13-19
pubmed: 31762693
Chest. 2002 Apr;121(4):1106-10
pubmed: 11948039
Ann Intern Med. 2019 Jan 1;170(1):W1-W33
pubmed: 30596876
Chest. 1995 Aug;108(2):349-54
pubmed: 7634865
Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):1039-42
pubmed: 18614551
Am J Surg. 2010 Apr;199(4):558-61
pubmed: 20359574
Med Oncol. 2017 Aug 9;34(9):159
pubmed: 28795306
J Thorac Cardiovasc Surg. 2004 Mar;127(3):779-86
pubmed: 15001907
Surg Today. 2017 Feb;47(2):252-258
pubmed: 27382978
Surg Today. 2016 Aug;46(8):877-86
pubmed: 26471506
Front Oncol. 2014 Oct 29;4:292
pubmed: 25401087
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Heart Vessels. 2020 Nov;35(11):1483-1493
pubmed: 32444933
Cancer Radiother. 2021 May;25(3):229-236
pubmed: 33423965
Ann Oncol. 2010 Sep;21(9):1825-1833
pubmed: 20211871
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):340-6
pubmed: 24336699
J Cardiothorac Vasc Anesth. 2015 Apr;29(2):396-401
pubmed: 25440618
Acta Oncol. 2020 Oct;59(10):1193-1200
pubmed: 32678696
Medicine (Baltimore). 2016 Oct;95(41):e5051
pubmed: 27741117
Gen Thorac Cardiovasc Surg. 2018 Feb;66(2):95-100
pubmed: 29134538
J Thorac Cardiovasc Surg. 1993 Dec;106(6):1104-10
pubmed: 8246546
J Cardiothorac Surg. 2013 Dec 01;8:220
pubmed: 24289748
Front Oncol. 2020 Jun 05;10:790
pubmed: 32582539
J Thorac Oncol. 2018 Oct;13(10):1508-1518
pubmed: 29883836
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Chest. 2001 Dec;120(6):1783-90
pubmed: 11742902
Ultrasound Med Biol. 2019 Jan;45(1):98-107
pubmed: 30366608
Int J Radiat Biol. 2015;91(10):804-9
pubmed: 25955228
Eur J Cardiothorac Surg. 2012 May;41(5):1094-7; discussion 1097
pubmed: 22219455
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):70-79
pubmed: 28816165
Radiother Oncol. 2013 Oct;109(1):100-6
pubmed: 24044794
Biophys Rev. 2019 Feb;11(1):111-118
pubmed: 30182201

Auteurs

Fariba Tohidinezhad (F)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Francesca Pennetta (F)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Judith van Loon (J)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Andre Dekker (A)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Dirk de Ruysscher (D)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Alberto Traverso (A)

Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, Netherlands.

Classifications MeSH